2 citations,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.
9 citations,
August 2019 in “Clinical genitourinary cancer” Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.
22 citations,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
45 citations,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.
1 citations,
March 2021 in “F1000Research” Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
33 citations,
January 2016 in “Skin appendage disorders” The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
37 citations,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
15 citations,
December 2006 in “Clinical interventions in aging” 5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.
34 citations,
August 2011 in “Journal of Natural Medicines” Puerariae Flos extract may help treat hair loss by blocking a hair loss-related enzyme and promoting hair growth.
124 citations,
September 1992 in “Endocrinology” The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.
76 citations,
September 1992 in “Endocrinology” The human type II 5α-reductase gene has a specific structure important for understanding certain medical conditions.
26 citations,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
11 citations,
August 2014 in “Current Urology Reports” Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.
April 2018 in “The Journal of Urology” Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
3 citations,
November 2010 in “Wiley-VCH Verlag GmbH & Co. KGaA eBooks” Finasteride safely treats enlarged prostate and male-pattern baldness.
2 citations,
January 2019 in “Annals of Dermatology” Melandrium firmum extract helps mice grow hair by blocking a hair loss enzyme and changing hair growth genes.
6 citations,
March 2015 in “Journal of Endocrinological Investigation” Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
1 citations,
April 2012 in “Daehan namseong gwahag hoeji” Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.
15 citations,
November 2015 in “Pharmacopsychiatry” α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.
24 citations,
February 2007 in “Hormone and metabolic research” The substance MK386 effectively blocked testosterone conversion and reduced cell growth in certain skin cells, but inhibiting 5α-reductase alone may not greatly improve acne.
30 citations,
December 1999 in “Journal of Investigative Dermatology Symposium Proceedings” Steroids, particularly estrogens and 5α-reductase inhibitors, affect blood vessel-related hair growth processes in hair follicle cells.
23 citations,
April 2021 in “Journal of Clinical Medicine” Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.
1 citations,
July 2018 in “Current Sexual Health Reports” Post-finasteride Syndrome causes lasting negative effects, but more research is needed for treatment and risk evaluation.
20 citations,
January 2003 in “Chemical and Pharmaceutical Bulletin” The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
December 2018 in “Reactions Weekly” Some medications may cause lasting sexual dysfunction.
17 citations,
May 2008 in “Pharmacopsychiatry” Finasteride improved symptoms in a schizophrenia patient.
20 citations,
January 2018 in “Expert Opinion on Drug Safety” Personalized treatment with inhibitors, minoxidil, and laser therapy helps hair loss.
February 2024 in “International Journal of Molecular Sciences” Hair loss in Androgenetic Alopecia is caused by genetics, aging, and lifestyle, leading to hair follicle shrinkage and related health risks.